采用免疫组化技术，从１９９３年初开始前瞻性研究，测定乳腺癌中雌激素受体表达，并观察其临床生物学意义。至１９９４年底共检测１７５例乳腺癌，其中雌激素受体（ＥＲ）阳性９９例，阴性７６例。ＥＲ阳性率为５６．５７％，经统计学分析，ＥＲ阳性率与病人年龄，月经状况，肿瘤大小，临床分期，淋巴结有无转移及病理组织类型无显著相关性（Ｐ＞０．０５），ＥＲ测定的意义在于指导临床选择治疗方案和判定预后 Using immunohistochemical techniques, a prospective study began in early 1993 to determine the expression of estrogen receptors in breast cancer and to observe its clinical biological significance. By the end of 1994, a total of 175 cases of breast cancer were examined, of which 99 cases were positive for estrogen receptor (ER) and 76 cases were negative. The positive rate of ER was 56.57%. Statistical analysis showed that the positive rate of ER was not significantly associated with the patient’s age, menstrual status, tumor size, clinical stage, lymph node metastasis and pathological type (P>0.05). The significance of ER measurement is to guide the clinical choice of treatment plan and determine the prognosis